China Resources Pharmaceutical Group Limited (HKG: 3320)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 34.11B |
| Revenue (ttm) | 269.14B |
| Net Income (ttm) | 4.06B |
| Shares Out | 6.28B |
| EPS (ttm) | 0.64 |
| PE Ratio | 8.51 |
| Forward PE | 6.94 |
| Dividend | 0.18 (3.26%) |
| Ex-Dividend Date | Sep 10, 2024 |
| Volume | 9,319,000 |
| Open | 5.46 |
| Previous Close | 5.46 |
| Day's Range | 5.41 - 5.50 |
| 52-Week Range | 4.45 - 7.11 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2024 |
About China Resources Pharmaceutical Group
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and v, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and... [Read more]
Financial Performance
In 2023, China Resources Pharmaceutical Group's revenue was 244.70 billion, an increase of 12.16% compared to the previous year's 218.18 billion. Earnings were 3.85 billion, an increase of 10.11%.
Financial numbers in CNY Financial StatementsNews
Health product chain store CR Care to close all 19 branches in Hong Kong in November
Health product chain CR Care will close all 19 of its Hong Kong branches next month, citing “external uncertainties” and various “operational challenges.” In a Facebook post shared on Tuesday, the cha...